Allworth Financial’s Standard BioTools LAB Stock Holding History

Allworth Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.36K	Buy	1,481 +790	+114%	+$956	﹤0.01%	4475
2025 Q4	$885	Sell	691 -113	-14%	-$152	﹤0.01%	4394
2025 Q3	$1.05K	Buy	804 +26	+3%	+$34	﹤0.01%	4236
2025 Q2	$934	Sell	778 -36	-4%	-$40	﹤0.01%	3978
2025 Q1	$1K	Buy	814 +114	+16%	+$160	﹤0.01%	3467
2024 Q4	$1.28K	Sell	700 -252	-26%	-$469	﹤0.01%	3319
2024 Q3	$1.84K	Buy	952 +107	+13%	+$210	﹤0.01%	3001
2024 Q2	$1.85K	Hold	845	–	–	﹤0.01%	2957
2024 Q1	$2.29K	Hold	845	–	–	﹤0.01%	2757
2023 Q4	$1.87K	Hold	845	–	–	﹤0.01%	2704
2023 Q3	$2.45K	Buy	845 +145	+21%	+$379	﹤0.01%	2446
2023 Q2	$1.35K	Hold	700	–	–	﹤0.01%	2640
2023 Q1	$1.36K	Buy	+700	New	+$1.38K	﹤0.01%	2555

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Allworth Financial's LAB Position: Q1 2026 in Review

Allworth Financial increased its Standard BioTools (LAB) stake by 114% in Q1 2026, buying an estimated $956 and bringing the position to 1,481 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Allworth Financial first reported a position in LAB in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.45K in Q3 2023. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Allworth Financial held 1,481 shares of Standard BioTools worth $1.36K as of Q1 2026.
Allworth Financial bought 790 Standard BioTools shares in Q1 2026, an estimated $956.
Standard BioTools made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4475 holding.
Allworth Financial first reported a position in Standard BioTools in Q1 2023 and has held it in 13 quarters since.
Allworth Financial's Standard BioTools position peaked at $2.45K in Q3 2023.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.